LGR5 and neoplasm: Interestingly, a patient-derived xenograft tumor model treated with Rspo1-conjugated doxorubicin liposomes targeting Lgr5+ CSCs showed significant tumor tissue necrosis and growth inhibition.[66] This drug delivery system using liposomes conjugated with the LGR5 ligand, which may reach more CSCs and deliver drugs efficiently, could provide an effective new strategy to treat cancer.